医药生物行业周报：药品零售新政出台，赋能行业高质量发展-20260126

Investment Rating - The report assigns an "Overweight" rating to the pharmaceutical and biotechnology industry, indicating that the industry is expected to outperform the broader market index (CSI 300) by at least 10% over the next six months [1]. Core Insights - The pharmaceutical and biotechnology sector experienced a slight decline of 0.39% during the week of January 19-23, 2026, ranking 27th among 31 sectors, while outperforming the CSI 300 index by 0.23 percentage points. The current PE valuation for the sector stands at 30.27 times, which is at the historical median level, with a valuation premium of 126% compared to the CSI 300 [5][16][23]. - The top-performing sub-sectors during this period were pharmaceutical commerce (4.26%), traditional Chinese medicine II (0.89%), and medical devices (0.30%) [5][14]. - A total of 330 stocks (69.62%) in the sector rose, while 137 stocks (28.90%) fell. The top five gainers included *ST Changyao (70.37%), Hualan Biological Engineering (32.21%), and Kangzhong Medical (25.47%) [5][31]. Market Performance - The pharmaceutical and biotechnology sector's performance for the year-to-date shows an increase of 6.66%, ranking 16th among 31 sectors and outperforming the CSI 300 index by 5.10 percentage points. The sub-sectors that achieved growth included medical services (13.53%), medical devices (9.50%), and pharmaceutical commerce (7.77%) [16][22]. - The PE valuations for various sub-sectors are as follows: medical devices (36.13), chemical pharmaceuticals (34.34), biological products (33.61), medical services (32.89), traditional Chinese medicine II (22.22), and pharmaceutical commerce (17.16) [23][30]. Industry News - On January 22, 2026, nine government departments, including the Ministry of Commerce and the National Health Commission, jointly issued guidelines aimed at promoting high-quality development in the pharmaceutical retail industry. The policy focuses on six key areas, emphasizing a combination of government guidance and market leadership to enhance professional and intensive development within the industry [6][33]. - The guidelines encourage the integration of pharmaceutical services, improvement of pharmacy service capabilities, and the promotion of prescription circulation and medical insurance outpatient coordination services. They also support the establishment of a commercial insurance payment system and the expansion of health management services [6][33][34]. Investment Recommendations - The report suggests a cautious approach to the pharmaceutical and biotechnology sector, highlighting the recent weak performance of previously popular stocks. It emphasizes the importance of the new guidelines in transforming the industry from a "single drug sales" model to a "health service" model [6][34]. - The report recommends focusing on leading chain pharmacies with strong financial capabilities and merger integration abilities, as well as innovative drug chains, medical devices, healthcare services, and second-class vaccines for potential investment opportunities [6][34][7].